We are delighted to invite you to a webinar exploring the evolving treatment landscape of metastatic triple negative breast cancer (mTNBC). Dr Mark Harries, Consultant Medical Oncologist at Guy’s and St Thomas’ in London will discuss the current and evolving treatment landscape of TNBC and introducing the newly approved antibody-drug conjugate (ADC), the first-in-class ADC that targets TROP-2, a commonly expressed marker in TNBC.
Läs mer...
We are delighted to invite you to a webinar focusing on caring for patients with metastatic triple negative breast cancer (mTNBC) from the nurse’s perspective. Nurse Anjali Sivajothu, Lead Clinical trials Practitioner at St Bartholomew’s Hospital in London will discuss how they manage patients with mTNBC.
Läs mer...
EMA has recommended granting a marketing authorisation in the European Union (EU) for Trodelvy (sacituzumab govitecan), a first-in-class medicine to treat adult patients with unresectable (cannot be removed by surgery) or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, at least one of them for advanced disease.
Läs mer...
8th October 2020, 16:00–18:00 We are pleased to welcome you to the 2nd Nordic CAR T symposium. This […]
Läs mer...
